Menu

Brain Prize Laureate Will Donate Some Winnings to Anti-Brexit Group

Alzheimer’s researcher John Hardy calls the departure “an unmitigated disaster” for science and healthcare in Britain.

Mar 6, 2018
Shawna Williams

ISTOCK, ANDREJ_KAt a press conference today (March 6), one of the four winners of this year’s Brain Prize, University College London neuroscientist John Hardy, turned attention to the impact of Britain’s impending exit from the European Union on science and healthcare in the country. The expected exodus of healthcare workers from other European countries will strain the ability of the U.K.’s National Health Service to care for the growing number of patients with dementia, Hardy predicts.

As reported in The Guardian, Hardy shares the €1 million prize with Bart De Strooper, also of University College London; Michel Goedert of the Medical Research Council Laboratory of Molecular Biology in Cambridge, U.K.; and Christian Haass of the Ludwig-Maximilians-University in Munich, for their discoveries on the mechanisms underlying Alzheimer’s disease.

See “Do Microbes Trigger Alzheimer’s Disease?

“When you go around the hospitals, so many of the geriatricians and neurologists are Europeans, and the nurses and carers,” Hardy said during the press conference (via The Guardian). “As a society we’re not doing very well, and the indications are we’re going to do even worse.” The BBC reports that he plans to donate about €5,000 to groups striving to keep Britain in the E.U.

Hardy is far from the first to predict dire consequences of Brexit for health and science. Ahead of the 2016 referendum on whether to remain in the E.U., for example, Nature found that 83 percent of researchers favored staying.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.